Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,487 JPY | -1.75% | -2.59% | -11.74% |
Sales 2024 | 1,604B 10.32B | Sales 2025 * | 1,661B 10.69B | Capitalization | 2,714B 17.47B |
---|---|---|---|---|---|
Net income 2024 | 17.04B 110M | Net income 2025 * | 89.55B 576M | EV / Sales 2024 | 1.84 x |
Net Debt 2024 * | 503B 3.24B | Net Debt 2025 * | 512B 3.3B | EV / Sales 2025 * | 1.94 x |
P/E ratio 2024 |
173
x | P/E ratio 2025 * |
30.4
x | Employees | 14,484 |
Yield 2024 |
4.26% | Yield 2025 * |
4.96% | Free-Float | 98.83% |
Latest transcript on Astellas Pharma Inc.
1 day | -0.75% | ||
1 week | -2.01% | ||
Current month | -0.03% | ||
1 month | +4.67% | ||
3 months | -8.41% | ||
6 months | -14.54% | ||
Current year | -10.23% |
Managers | Title | Age | Since |
---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 61 | 86-03-31 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 52 | Oct. 31 |
Kenji Yasukawa
CHM | Chairman | 63 | 86-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Takashi Tanaka
BRD | Director/Board Member | 67 | 21-05-31 |
Mamoru Sekiyama
BRD | Director/Board Member | 74 | 17-05-31 |
Naoki Okamura
CEO | Chief Executive Officer | 61 | 86-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.47% | 19 M€ | +11.47% | ||
2.09% | 240 M€ | +17.94% | ||
2.01% | 60 M€ | +22.25% | ||
1.99% | 10 M€ | +16.39% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 1,487 | -1.75% | 3 711 000 |
24-05-16 | 1,514 | -0.75% | 4,790,700 |
24-05-15 | 1,525 | +0.26% | 4,901,000 |
24-05-14 | 1,521 | +0.70% | 6,123,400 |
24-05-13 | 1,510 | -1.11% | 4,597,000 |
Delayed Quote Japan Exchange, May 16, 2024 at 02:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.23% | 17.66B | |
+32.36% | 709B | |
+30.77% | 595B | |
-1.60% | 367B | |
+20.07% | 334B | |
+6.04% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.27% | 171B |
- Stock Market
- Equities
- 4503 Stock